ibandronate sodium hydrate / Generic mfg. - LARVOL DELTA

Long-term cardiovascular and skeletal effects of bisphosphonate treatment in the first year after kidney transplantation; a 13-year prospective follow-up of a randomized controlled study of ibandronate vs placebo (ERA 2025) - No abstract available

Clinical • Cardiovascular • Transplantation

Meningeal malignant solitary fibrous tumor with multiple recurrence, extracranial extension, cervical lymph node metastases: case report and review of the literature. (PubMed, Discov Oncol) - "We report the first case of extracranial extension and cervical lymph node metastases from meningeal malignant SFT. This finding provides novel insights into the dissemination patterns of intracranial SFT. Surgical resection is the gold standard for the treatment. Postoperative radiotherapy (PORT) whether gross total resection (GTR) or subtotal resection (STR) may be the optimal treatment strategy, but PORT dose < 60 Gy with IMRT or marginal dose < 15 Gy with GKRS may be insufficient. Close and long-term follow-up, especially in the first five years after diagnosis, is essential to manage such patients because of high risk of recurrence and metastasis."

Journal • Brain Cancer • CNS Tumor • Meningioma • Oncology • Solid Tumor • Spindle Cell Sarcoma • CD34 • VIM

Time since last intravenous bisphosphonate and risk of osteonecrosis of the jaw in osteoporotic patients. (PubMed, Nat Commun) - "The risk reduction appears more consistent with ibandronate, whereas with zoledronate, only pauses longer than one year show a meaningful association. These findings underscore the potential value of personalized prevention strategies based on bisphosphonate type."

Journal • Retrospective data • Osteoporosis • Rheumatology

METHOD FOR INCREASING THE ULTRASONIC CONDUCTIVITY OF SKULL BONE TISSUE IN PATIENTS WHO ARE PLANNED TO BE TREATED WITH MAGNETIC RESONANCE IMAGING-GUIDED FOCUSED ULTRASONIC IMAGING (ESPE-ESE 2025) - "The patient for whom MR-FUS is planned undergoes CT of the cranial bones to determine the UPCCT, as well as laboratory tests for ionized calcium and vitamin D. If the coefficient is less than 0.35, the patient is administered Bonviva (Ibandronic acid) 3 mg intravenously by bolus over 15-30 seconds once every 3 months, Aquadetrim (Cholecalciferol) at a dose of 1500-5500 IU per day and Calcium D3 Nycomed (Calcium carbonate + Cholecalciferol) at a dose of 500 mg + 200 IU 2 times a day...If the cranial CUPCT increases by more than 0.35, the patient is referred for surgery using focused ultrasound. If there is no effect after 3 months."

Clinical • MRI • CNS Disorders • Dystonia • Endocrine Disorders • Essential Tremor • Movement Disorders • Parkinson's Disease

ACTH-independent Cushing's disease due to macronodular hyperplasia with a late diagnosis of Klinefelter's syndrome (ESPE-ESE 2025) - "Although post-operatively patient had an apparent normalization of adrenocortical function, he presented adrenocortical insufficiency (ACTH=4 pg/ml, cortisol 8AM=4.87ug/dl) requiring initiation of low-dose hydrocortisone replacement therapy...Management was done by administration of ibandronate and transdermic testosterone...The overlapping metabolic and hormonal clutter in Cushing’s syndrome can hide clinical presentation of Klinefelter’s syndrome, leading to delayed recognition and treatment of osteoporosis, but in the absence of fractures, most likely to have a positive outcome and improvement in bone mineral density. Rapid approach of Klinefelter in older patients may improve long-term results by addressing associated metabolic, cardiovascular and bone complications."

Cardiovascular • Cushing’s Disease • Diabetes • Endocrine Disorders • Genetic Disorders • Hypertension • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Systemic Mastocytosis Presenting as Recurrent Vertebral Compression Fractures (ENDO 2025) - "At this time he started ibandronate for one year before transitioning to risendronate for a total treatment duration of 2 years before discontinuation for unclear reasons...The patient since completed a course of teriparatide and most recently started treatment with zoledronic acid... Systemic mastocytosis is a rare but underrecognized cause of secondary osteoporosis and fragility fractures. Screening with serum tryptase should be considered in an adult with osteoporosis and pathologic bone fractures if no other risk factors for osteoporosis are identified or if other complementary features are present.*. .*"

Back Pain • Eosinophilia • Fatigue • Lumbar Back Pain • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Osteoporosis • Pain • Rheumatology

Atypical Femur Fractures-An Analysis of 69 Patients from 15 Years. (PubMed, J Clin Med) - "The duration of bisphosphonate use prior to the development of AFF was comparable between alendronate, ibandronate, and a history of using more than one type of anti-resorptive agent. AFF is more commonly seen in female patients with a history of bisphosphonate use. Considering the high success rate demonstrated in the current cohort, treating AFF with closed reduction followed by fixation with a long cephalomedullary device in dynamic locking together with immediate full-weight-bearing rehabilitation post-operation may be effective."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Activation of autophagy mediated by PI3K/Akt/mTOR signalling cascade alleviates impaired adipose-derived stem cell osteogenesis in a diabetic microenvironment. (PubMed, Br J Pharmacol) - "AGEs decreased the osteogenesis of ASCs by activating PI3K/Akt/mTOR signalling cascade and blocking autophagic flux. Autophagy induced by blocking the PI3K/Akt/mTOR signalling cascade could rescue the negative influences of ASCs in diabetic environment and provide a potential therapeutic strategy for bone renewal in individuals with DOP."

Journal • Osteoporosis • Rheumatology • RUNX2

Navigating skeletal wellness after breast cancer. (PubMed, Maturitas) - "Nowadays, clodronate, ibandronate, and zoledronic acid are recommended for bone protection in this group of patients, while denosumab is not. Further research is required to highlight the optimal BMA according to patient characteristics."

Journal • Review • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Musculoskeletal Diseases • Oncology • Osteoporosis • Solid Tumor

Risk of jaw osteonecrosis and atypical femoral fracture: how to inform patients with osteoporosis? (PubMed, Ther Umsch) - "Amino-bisphosphonates (BP), such as zoledronate, alendronate, ibandronate or risedronate, and the antibody therapies with denosumab (DMAb) or romosozumab (ROMO) are highly effective therapies for reducing the risk of vertebral fractures and non-vertebral fractures in patients with osteoporosis. This association leads to uncertainty among patients and treating physicians as to how the benefit-risk should be assessed in individual cases. By providing concrete answers to specific questions in connection with these rare events, patients can be informed in a targeted manner."

Journal • Review • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Pharmacogenetics of Response to Bisphosphonate Treatment in Postmenopausal Osteoporosis: A Prospective Study. (PubMed, J Bone Metab) - "These findings did not support the potential role of VDR BsmI, Col1a1 Sp1, ER1 PvuII, or XbaI polymorphisms in predicting the response to BP therapy in women with postmenopausal OP. Further investigation with larger prospective studies is required."

Biomarker • Journal • Osteoporosis • Rheumatology • BGLAP • COL1A1 • ER

Case series: Chemical pneumonitis caused by exposure of sodium ibandronate powder. (PubMed, Front Public Health) - "The findings suggest that the importance of appropriate safety measures in environments where pharmaceutical powders may be handled, such as in the pharmaceutical industry. Chemical pneumonitis from inhaled sodium ibandronate can have varying CT appearances and may benefit from glucocorticoids therapy."

Journal • Fibrosis • Inflammation • Osteoporosis • Pneumonia • Rheumatology

Cost-Effectiveness of Bisphosphonates in Preventing Periprosthetic Fracture After Hip Arthroplasty (AAOS 2025) - "Four bisphosphonates were identified (Alendronate, Ibandronate, Risedronate, and Zoledronate) with annual costs ranging from $10.45-92.56 according to the National Average Drug Acquisition Cost database. If bisphosphonates are clinically efficacious in reducing periprosthetic hip fracture risk, preoperative therapy is an economically viable intervention across a range of medications and baseline fracture rates. Given prior studies have shown strong correlation between osteoporosis undertreatment and periprosthetic fracture risk, our study deems this intervention highly cost-effective."

Cost effectiveness • HEOR • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Effects of Sequential Anti-Resorptive Agents on Bone Mineral Density Following Denosumab Withdrawal: A Multicenter Real-World Study in Korea (MAXCARE Study). (PubMed, Endocrinol Metab (Seoul)) - "This retrospective study included 360 patients (low-dose alendronate/calcitriol combination [MXM, n=118], alendronate [ALD, n=53], risedronate [RIS, n=20], ibandronate [IBN, n=30], zoledronic acid [ZOL, n=106], selective estrogen receptor modulator [SERM, n=33]) who received at least 12 months of post-denosumab anti-resorptive therapy. Conversely, RIS, IBN, and SERM did not adequately prevent BMD decline. These findings underscore the importance of selecting the most appropriate sequential antiresorptive therapy in clinical practice to minimize BMD loss and reduce the risk of adverse outcomes."

Journal • Real-world evidence • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Changing trends in bisphosphonate therapy: a twenty-five-year surveillance in a single US integrated healthcare system. (PubMed, Osteoporos Int) - "In a large primary care population of adults initiating BP, greater treatment of older adults and those with prior fracture highlights the key role of targeted fracture prevention initiatives, sustaining treatment efforts."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Novel Approaches to Monitor Pharmacokinetics and Metabolism of Gemcitabine-Ibandronate Conjugate in Mice and Dogs. (PubMed, Molecules) - "Pharmacokinetic studies in dogs and mice showed that GEM-IB is rapidly converted to IB and GEM; dFdU is formed (from GEM) with a delay. The rapid disappearance of GEM-IB from circulation could be explained by a combination of metabolism and rapid distribution to tissue/bone."

Journal • PK/PD data • Preclinical • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Evaluation and analysis of efficacy in bisphosphonate treatment of chronic nonbacterial osteomyelitis. (PubMed, Hua Xi Kou Qiang Yi Xue Za Zhi) - "Bisphosphonate could be used to treat chronic nonbacterial osteomyelitis, which of efficacy were affected by different drug types, dose and frequency of administration. The optimal dose and frequency of administration of pamidronate were 0.5-1 mg/kg (maximum single dose≤60 mg) and once every 3 months, respectively."

Journal • Inflammation

A Case of Diffuse Sclerosing Osteomyelitis (DSO) Initially Diagnosed as Bacterial Mandibular Osteomyelitis and Successfully Treated With Bisphosphonate Administration (Ibandronate). (PubMed, Cureus) - "This case highlights the importance of prompt diagnosis and appropriate treatment of DSO, which differs from bacterial mandibular osteomyelitis. Bisphosphonate administration is an effective treatment that contributes to the long-term course of the disease."

Journal • Dental Disorders • Infectious Disease • Inflammation • Pain • Periodontitis

Effectiveness of Bisphosphonates in Young Adults with Fragility Fractures: Representative Population-Based Cohort Study. (PubMed, J Clin Endocrinol Metab) - "Bisphosphonate therapy significantly reduces fracture risk in premenopausal women with previous osteoporotic fractures, especially at higher cumulative doses. These findings support considering bisphosphonates as a treatment option in premenopausal women at high risk of fractures."

Journal • Musculoskeletal Diseases • Orthopedics

Fractures Post Lung Transplant: A Retrospective Cohort Study Conducted at an International Transplant Center (ACR Convergence 2024) - "Prior to LT, 403 patients were treated with OP medication (alendronate, 225 patients; zoledronic acid, 67 patients; ibandronate 40 patients, denosumab 17 patients) (Table 1). Pre-LT osteopenia, OP, smoking history, and alcohol use are strong predictors of post-LT fracture, highlighting the importance of OP management prior to and after LT. Denosumab is a safe and effective medication post-LT and it is associated with a 65% reduction in the odds of having a post-LT OP fracture. This is a novel finding among post-LT patients and has not been demonstrated elsewhere."

Retrospective data • Dermatology • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Transplantation

Tibial Insufficiency Fracture with Characteristics of an Atypical Fracture: A Rare Case and Literature Review. (PubMed, Medicina (Kaunas)) - "She had been receiving long-term bisphosphonate therapy for osteoporosis, initially taking sodium risedronate orally for 4 years, followed by intravenous ibandronate for 10 years. Clinicians should consider this possibility when patients present with pain in weight-bearing bones without a history of trauma. Prompt diagnosis through thorough history-taking, physical examination, and appropriate imaging is essential to ensure timely management."

Journal • Review • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Pain • Rheumatology

Hip geometry and strength remain stable the first year after kidney transplantation-an ibandronate/placebo post hoc analysis. (PubMed, JBMR Plus) - P2/3 | "In this study, the so far largest of HSA in KTR, antiresorptive therapy with ibandronate for 12 months did not affect measures of hip geometry or strength. Clinical Trial Registration: www.clinicaltrials.gov as NCT00423384, EudraCT number 2006-003884-30."

Clinical • Journal • Retrospective data • Musculoskeletal Diseases • Orthopedics • Transplantation

Disproportionality analysis of oesophageal toxicity associated with oral bisphosphonates using the FAERS database (2004-2023). (PubMed, Front Pharmacol) - "We systematically extracted data on adverse reactions to oral alendronate, risedronate, and ibandronate from the FAERS database, covering the period from the 2004 Q1 to the 2023 Q4. Hospitalization rates varied significantly among patients receiving different BPs (p < 0.05), but no significant difference in mortality rates was found. The study establishes a significant link between oral BPs and oesophageal toxicity, highlighting the need for further research into the mechanisms of BP-induced oesophageal toxicity and potential preventive measures."

Adverse events • Journal • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Pain

Endodontic and periapical status of patients with osteoporosis: A cross-sectional study with age- and sex-matched controls. (PubMed, J Am Dent Assoc) - "Dentists can collaborate with health care professionals to manage the overall health of patients with osteoporosis to reduce the impact of osteoporosis on oral health and effectively treat dental problems, such as AP."

Journal • Observational data • Dental Disorders • Inflammation • Osteoporosis • Periodontitis • Rheumatology

Utilization and Expenditure on Medicines for the Prevention and Treatment of Osteoporosis: A Changing Landscape (ISPOR-EU 2024) - "Data was included on claims from 1st January 2011 to 31 December 2023 for dispensed medicines that are licensed for the management of osteoporosis; bisphosphonates (alendronate, ibandronate, risedronate), teriparatide, denosumab, selective oestrogen receptor modulators (SERMS) (raloxifene, bazedoxifene) and tibolone. This study highlights the changing landscape of osteoporosis prevention and treatment in Ireland, over a 13-year period. Further research into treatment adherence with these therapies is warranted, given an aging population and attendant increase in fractures with associated healthcare resource use."

Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology